Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Sponsor
Vejle Hospital
Study ID
NCT00827684
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.

Key Dates

Start date
Mar 31, 2009
Status verified
Jun 2011
Primary completion
Jan 31, 2011
Completion
Jun 30, 2011

Study Design

Enrollment
50 participants (estimated)
Primary purpose
TREATMENT

Arms

  • Active Comparator: Response or stable disease
    will receive Temsirolimus
  • Experimental: Progression
    Will receive a combination of Temsirolimus and Irinotecan

Primary Outcome Measure

Objective response rates

Related Studies